Product Highlight - SOLIQUA

16 Jun 2021
Product Highlight - SOLIQUA

                                                                                   Experience the Power to Control!1,2,3
                                                                                       Now available at a lower price!4

  • Insulin Glargine + Lixisenatide (Soliqua®) 100 u/mL + 50 mcg/ml – NEW SRP Php 1,515 (Savings of Php 318 from previous SRP)4
  •  Insulin Glargine + Lixisenatide (Soliqua®) 100 u/mL + 33 mcg/ml – NEW SRP Php 1,313 (Savings of Php 348 from previous SRP)4
  •  Indicated for the treatment of type 2 diabetes mellitus in adults to improve glycemic control when oral antidiabetic drugs or basal insulin alone do not provide adequate
    glycemic control.1-3
  •  Power to control HbA1c with no added risk of hypoglycemia and no weight gain.1-3



REFERENCES:
(1) Soliqua 2018 Prescribing Information.
(2) Rosenstock J et. al. LixiLan-O randomized trial. Diabetes Care. 2016 Nov 1;39(11):2026-35.
(3) Aroda et. al. LixiLan-L randomized trial. Diabetes care. 2016 Nov 1;39(11):1972-80.
(4) Based on Mercury Suggested Retail Price as of July 1, 2020.

This material is strictly for HCPs only.


sanofi-aventis Phils. Inc.
21st to 23rd Flr. One World Place Corporate Offices. 32nd St.
Bonifacio Global City, Taguig City 1634, Metro Manila
Website: www.sanofi.ph

Related MIMS Drugs